APCCC 2024: The Best Use of PARP Inhibitors in mCRPC
APCCC 2024, prostate cancer, Metastatic Castration Resistant Prostate Cancer (mCRPC), PARP Inhibitors, BRCA-deficient metastatic prostate cancer, TOPARP-B trial, olaparib, olaparib monotherapy, PROFOUND trial, androgen receptor pathway inhibitor (ARPI), olaparib versus ARPI, BRCAAWAY trial, TRITON2 trial, TRITON3 trial.